New syringe could simplify High-Dose eye treatment
NCT ID NCT05989126
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a pre-filled syringe containing a high dose (8 mg) of the drug aflibercept for two eye conditions: diabetic macular edema and wet age-related macular degeneration. The main goal was to see if retina specialists could prepare and inject the drug easily and safely using the syringe. The study involved 35 participants and focused on the device's usability and safety, not on how well the drug treats the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept (high dose 8 mg)
- What this could lead to
- If successful, this could make it easier and safer for retina specialists to give high-dose aflibercept injections for common eye diseases.
- What could go wrong
- This is a small, completed study focused on syringe usability, not on whether the drug works better. Results may not change treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Retina Consultants of Texas
The Woodlands, Texas, 77385, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy tame wet AMD for years?
- Laser zap before eye injection could cut needle count for wet AMD
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New eye injection shows promise for wet AMD in everyday practice